Assessment of Pouch Emptying With MRI After Roux-en-Y Gastric Bypass (MRI pouch)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
-
Arnhem, Netherlands, 6815 AD
- Yonta Burgh
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Women aged between 20 and 55 years
- Patients must be able to adhere to the study visit schedule and protocol requirements
- Patients must be able to give informed consent (IC) prior to any study procedures
- Patients who had a follow-up period up until two years after LRYGB and have successful or unsuccessful weight loss.
- Willing to be informed about incidental findings of pathology and approving of reporting this to their general physician
Exclusion Criteria:
- Diabetes Mellitus
- Menopausal
- Gastrointestinal problems, gastric or intestinal diseases
- Drug or alcohol addiction
- Inability to stop smoking during the overnight fasting period
- Pregnant or lactating
- Having an intolerance or allergy for one of the components of the test product
- Inability to stop medications that affect gastrointestinal emptying like antisecretory drugs, narcotics and prokinetic agents
- Inability to stop medication that affects the motility of the upper gastrointestinal tract (anti-cholinergic drugs, prokinetics, theophylline, calcium blocking agents, opioids)
Having a contra-indication to MRI scanning (including, but not limited to):
- Pacemakers and defibrillators
- Intraorbital or intraocular metallic fragments
- Ferromagnetic implants
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
RYGB, successful weight loss (TWL >35%)
TWL = total weight loss
|
no intervention.
MRI measurement.
Observation.
|
|
RYGB, unsuccessful weight loss (TWL <25%)
|
no intervention.
MRI measurement.
Observation.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Pouch emptying rate measured with MRI
Time Frame: Two years after LRYGB
|
Two years after LRYGB
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
subjective ratings of fullness
Time Frame: Two years after LRYGB
|
subjective ratings of fullness will be measured an a 100-unit Visual Analogue Scale
|
Two years after LRYGB
|
|
subjective ratings of wellbeing
Time Frame: Two years after LRYGB
|
subjective ratings of wellbeing will be measured an a 100-unit Visual Analogue Scale
|
Two years after LRYGB
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 2018-1279
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.